São Paulo - Delayed Quote BRL

Eli Lilly and Company (LILY34.SA)

161.28

+4.76

+(3.04%)

As of 2:09:09 PM GMT-3. Market Open.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Zacks 1 hour ago

LLY

PFE
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Zacks 1 hour ago

ROG.SW

LLY
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Zacks 2 hours ago

NVO

LLY
Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market. Orforglipron is a GLP-1 receptor agonist that works similarly to medications like Novo’s Ozempic. The pill mimics the effects of the hormone glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar levels.

Barrons.com 3 hours ago

LLY
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 hours ago

LLY

PFE
Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on […]

Insider Monkey 16 hours ago

LLY
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.

Pharmaceutical Technology 23 hours ago

LLY
Eli Lilly is stepping up its fight against copycat weight loss drugs

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.

Quartz yesterday

LLY
Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'

All three major US stock indexes were up sharply, with the Nasdaq Composite gaining nearly 3% in lat

PREMIUM
MT Newswires yesterday

BA

LLY

TSLA
Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming […]

Insider Monkey yesterday

LLY
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.

Motley Fool yesterday

LLY
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. While Seigerman waxed bullish about the company's hottest product at the moment (obesity drug Zepbound), he expressed concerns about the broader macroeconomic environment.

Motley Fool yesterday

LLY
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected. The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.

Motley Fool yesterday

NVO

LLY
Lilly sues four compounders over copies of weight-loss drugs

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines. Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps. Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.

Reuters yesterday

LLY
Is Eli Lilly Stock a Buy?

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Motley Fool yesterday

LLY

NVO
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note

Eli Lilly (LLY) closed at $827.54 in the latest trading session, marking a +1.16% move from the prior day.

Zacks yesterday

LLY
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Investor's Business Daily yesterday

PFE

LLY

NONOF
Q1 Earnings Season Scorecard and Analyst Reports for NVIDIA, Alphabet & Berkshire Hathaway

Today's Research Daily features a real-time update on the Q1 earnings season, in addition to updated research reports on 16 major stocks, including NVIDIA (NVDA), Alphabet (GOOGL) and Berkshire Hathaway Inc. (BRK.B).

Zacks yesterday

NVDA

GOOG

BRK-B
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom

President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system. While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.” A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.

Barrons.com 2 days ago

ABBV

LLY

REGN
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. Three Fool.com contributors believe they've identified relatively safe growth stocks in the healthcare sector that you can buy and hold. Here's why they picked Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).

Motley Fool 2 days ago

VRTX

LLY

AMGN

Performance Overview

Return	LILY34.SA	S&P 500 (^GSPC)
YTD	+0.96%	-6.99%
1-Year	+28.61%	+7.86%
3-Year	+269.17%	+28.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LILY34.SA)

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success

Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

Eli Lilly is stepping up its fight against copycat weight loss drugs

Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'

Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?

Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Lilly sues four compounders over copies of weight-loss drugs

Is Eli Lilly Stock a Buy?

Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Q1 Earnings Season Scorecard and Analyst Reports for NVIDIA, Alphabet & Berkshire Hathaway

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

Performance Overview